Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04617145
Other study ID # MA201918
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date April 1, 2018
Est. completion date October 1, 2020

Study information

Verified date October 2020
Source Cairo University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Sixty patients with AML from both sexes aged from 35-45 years were selected from hematology department in Nasser Institute Hospital where the study was conducted. Patients were randomly assigned into two groups equal in number. Group (A) underwent aerobic exercises in the form of cycling with 50-60% of maximum heart rate. Group (B) underwent resistive training conducted in the form of a series of exercises using free weights, and dumbles. Sessions were conducted three times /week for eight weeks. Six minutes' walk test (6MWT), 10 repetitions maximum test (10 RM), ventilatory function test, fatigue and quality of life (QOL) scales were used to assess functional capacity in both groups.


Description:

Aerobic Ex Group: Included 30 patients who underwent aerobic training with 50 %-60% of maximum heart rate in the form of cycling by Bicycle ergometer for eight weeks, three sessions/week. Resistive Ex Group: Included 30 patients who underwent a resistive training which were conducted in the form of a series of exercises using free weights, and dumbles to increase the strength of arms, pectoral muscles, abdominal, back muscles and gluteal region. Patients carried out three sets of 20-30 dynamic repetitions or static isometric exercises for 40-60 seconds for each muscle group and rested 1-2 min between series. Sessions were conducted three sessions/week for eight weeks.


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date October 1, 2020
Est. primary completion date June 2, 2020
Accepts healthy volunteers No
Gender All
Age group 35 Years to 45 Years
Eligibility Inclusion Criteria: - Acute myeloid leukemia survivors from both sexes - Their age ranged from 35-45 years. - Patients were in remission stage contains less than 5% blast cells in their bone marrow, absolute neutrophil count (>1000/microL), platelet count(>100,000/microL),and independence from red cell transfusion. Exclusion Criteria: - Extramedullary leukemia - musculoskeletal deformities - severe anemia (hemoglobin less than 8g/dl). - Autoimmune thrombocytopenia (platelets less than 10000UL or leucocytes count more than 3000UL).

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Aerobic exercise
resistive training which were conducted in the form of a series of exercises using free weights, and dumbles to increase the strength of arms, pectoral muscles, abdominal, back muscles and gluteal region. Patients carried out three sets of 20-30 dynamic repetitions or static isometric exercises for 40-60 seconds for each muscle group and rested 1-2 min between series. Sessions were conducted three sessions/week for eight weeks.

Locations

Country Name City State
Egypt Faculty of Physical Therapy Giza Cairo

Sponsors (1)

Lead Sponsor Collaborator
Cairo University

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary Six minutes walking Distance which used to measure the distance the patient was able to walk over a total of six minutes According to American thorax society guidelines; patients were instructed to walk as fast as long as possible , in a 30 meters obstacle free corridor limited by turnaround cones and distance was calculated It is performed before and after the study(8 weeks interval) for both groups
Primary 10 repetition maximum test which the greatest amount of weight a person can lift number of times. The amount of weight that can be lifted exactly 10 times is 10 RM It is performed before and after the study(8 weeks interval) for both groups
Primary Vital capacity was measured by using electronic spirometry used to conduct ventilatory function testing It is performed before and after the study(8 weeks interval) for both groups
Secondary Maximum oxygen consumption Results of (6MWT) was used to calculate Vo2 max by using Cahalin equation as follows; Vo2 max = 0.03x distance in meters +3.98, in which distance is obtained from (6MWT) It is performed before and after the study(8 weeks interval) for both groups
Secondary Fatigue assessment scale (FAS) FAS is a 10-item scale evaluating symptoms of chronic fatigue It is performed before and after the study(8 weeks interval) for both groups
Secondary Quality of life questionnaire (QOL) was used to evaluate the quality of life before and after training for both groups.The Quality of Life Instrument (CANCER PATIENT/CANCER SURVIVOR VERSION) is a forty one-item ordinal scale. The scoring should be based on a scale of 0 = worst outcome to 10 = best outcome It is performed before and after the study(8 weeks interval) for both groups
See also
  Status Clinical Trial Phase
Recruiting NCT03887156 - Evaluation of a Donor Testing Kit for the Prediction of AGVHD in Patient Receiving a Peripheral Blood Stem Cell Allograft Phase 2/Phase 3
Recruiting NCT05917405 - Study Comparing the Efficacy of 2 RIC Regimens (Clofarabine vs Fludarabine) in Adults With AML Eligible to Allo-SCT Phase 2
Recruiting NCT04062266 - AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission Phase 2
Recruiting NCT04490707 - Study of Azacytidine Combined With Lenalidomide As Maintenance Therapy Based on MRD Monitoring in AML Phase 3
Terminated NCT03272633 - Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies Early Phase 1
Active, not recruiting NCT00075478 - Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer Phase 3
Active, not recruiting NCT03697707 - Efficacy and Safety of Immunotherapy With Allogeneic Dendritic Cells, DCP-001, in Patients With Acute Myeloid Leukaemia Phase 2
Active, not recruiting NCT02506933 - Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant Phase 2
Recruiting NCT03286530 - Ruxolitinib + Allogeneic Stem Cell Transplantation in AML Phase 2
Withdrawn NCT02528877 - Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis Phase 1
Active, not recruiting NCT01894477 - Treo/Flu/TBI With Donor Stem Cell Transplant for Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Phase 2
Recruiting NCT04232241 - Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia Phase 2
Active, not recruiting NCT02566304 - Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies Phase 2
Active, not recruiting NCT01619761 - NK Cells in Cord Blood Transplantation Phase 1
Terminated NCT01028716 - Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Phase 2
Recruiting NCT05794880 - MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing N/A
Completed NCT02083250 - Fludarabine Phosphate, Clofarabine, and Busulfan With Vorinostat in Treating Patients With Acute Leukemia in Remission or Relapse Undergoing Donor Stem Cell Transplant Phase 1
Active, not recruiting NCT02446964 - Total Marrow and Lymphoid Irradiation and Chemotherapy Before Donor Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Leukemia Phase 1
Recruiting NCT04747002 - Investigator-initiated Clinical Trial (Phase II) of Cancer Vaccine "Dainippon Sumitomo Phama(DSP)-7888" for Acute Myeloid Leukemia Patients. Phase 2
Completed NCT01823198 - Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies Phase 1/Phase 2